Becton Dickinson and Co (BDX)
適正価値ファンダメンタル
60
株価
$179.00
時価総額
$50.07B
パート1 · 企業の価値
概要
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Baxter sells infusion pumps, IV sets and injectable drug delivery systems to the same hospital pharmacies and purchasing groups that buy BD's medication delivery and infusion business.
After absorbing Hospira's infusion business, ICU Medical bids against BD for hospital contracts on infusion pumps, IV sets and vascular access consumables.
Abbott competes with BD's Life Sciences arm for hospital laboratory budgets, supplying diagnostic instruments and infectious-disease testing systems to the same clinical labs.
This family-owned German group competes with BD across the whole IV therapy line — catheters, infusion pumps, syringes and needles — in hospitals in Europe and the United States.
Teleflex competes head-on with BD's interventional and vascular access catalogue, above all central venous and PICC catheters bought by the same hospital departments.
Medtronic overlaps with BD on needles and syringes and on vascular and urology intervention devices sold to the same surgical and interventional specialists.
貸借対照表と流動性
売上高
$22.41B
直近12か月（2026/6/30まで）
純利益
$941M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$2.67B
自己資本合計
$25.39B
負債合計
$29.93B
流動比率
0.87
利払い倍率
3.92
負債/EBITDA
3.33
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$216.42
現在株価
$179.00
安全マージン
+17.3%
適正価値レンジ
$140.67 - $292.17
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
54.08
ROE
6.6%
P/B レシオ
2.00
P/FCF
15.22
粗利益率
46.7%
ROIC
4.4%
収益性レーダー
価値創造（経済的モート）
ROIC
4.4%
WACC
6.7%
ROIC − WACC
-2.3 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（17）
- EPS shows upward trend
- Gross Margin 46.7%
- P/FCF 15.22
- P/B Ratio 2.00
- Debt/Equity ratio
- Operating Margin 10.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 6.3%
- Analyst Consensus 57% Buy
- Earnings Quality (OCF/NI) 4.20
- Share Dilution -0.9%
- Piotroski F-Score 8/9
不合格（10）
- EPS CAGR 2.88%
- Price CAGR 3.43%
- ROIC 4.4%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
- Earnings Surprise avg 1.9%
- PEG Ratio 3.94
- Net Margin Trend 4.2% vs 8.0%
データなし（1）
- Dividend Payout NaN%
Piotroski F-スコア
財務健全性が高い
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 52 |
| Dr. Michael D. Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | 55 |
| Mr. Michael C. Feld | Executive VP & Chief Revenue Officer | 44 |
| Mr. Vitor Roque | Executive VP & CFO | 42 |
| Ms. Elizabeth McCombs | Executive VP & CTO | 48 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | - |
| Ms. Denise Russell Fleming | Executive Vice President & Chief Information Officer | 54 |
| Mr. Shawn C. Bevec | Senior Vice President of Investor Relations | - |
| Ms. Lanesha T. Minnix J.D. | Executive VP & General Counsel | 50 |
| Carla Burigatto | Senior VP & Chief Communications Officer | - |
監査リスク
3
取締役会リスク
6
報酬リスク
5
株主権利リスク
1
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for BDX, sourced from Markets Gazette.